In their recent critical analysis of the JUPITER (Justification for the Use of Statins in Primary Prevention) study, de Lorgeril and colleagues1 expanded the debate regarding the applications of statin therapy for primary prevention of cardiovascular disease and mortality. They identified both procedural and outcomes irregularities that led them to conclude that JUPITER does not support the use of statins for primary prevention. This conclusion was echoed by Ray et al2 in their meta-analysis of all-cause mortality in 11 randomized trials of statin therapy involving more than 65 000 high-risk primary prevention subjects.
Pippin JJ. Primary Prevention Cardiovascular Disease: Better Than Drugs. Arch Intern Med. 2010;170(20):1860–1861. doi:10.1001/archinternmed.2010.402